WO2010103544A3 - A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants - Google Patents

A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants Download PDF

Info

Publication number
WO2010103544A3
WO2010103544A3 PCT/IN2010/000137 IN2010000137W WO2010103544A3 WO 2010103544 A3 WO2010103544 A3 WO 2010103544A3 IN 2010000137 W IN2010000137 W IN 2010000137W WO 2010103544 A3 WO2010103544 A3 WO 2010103544A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained release
muscle relaxants
combination
class
provides
Prior art date
Application number
PCT/IN2010/000137
Other languages
French (fr)
Other versions
WO2010103544A2 (en
WO2010103544A4 (en
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Original Assignee
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinesh Shantilal Patel, Sachin Dinesh Patel, Shashikant Prabhudas Kurani filed Critical Dinesh Shantilal Patel
Priority to EP10740754A priority Critical patent/EP2405900A2/en
Priority to CN2010800196712A priority patent/CN102438597A/en
Priority to EA201171109A priority patent/EA201171109A1/en
Publication of WO2010103544A2 publication Critical patent/WO2010103544A2/en
Publication of WO2010103544A3 publication Critical patent/WO2010103544A3/en
Publication of WO2010103544A4 publication Critical patent/WO2010103544A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

The disclosed invention provides novel sustained release pharmaceutical preparations and process for making such compositions of Tolperisone and/or Eperisone and/or a pharmaceutically acceptable salt thereof. The present invention provides a sustained release formulation of Tolperisone and Eperisone either single or in combination or otherwise in combination with other drugs selected from the classes such as analgesic, antipyretic, neuroprotective agents, other muscle relaxants which can be formulated either in a fixed dose or as combination kit for oral administration. The composition is suitable for once a day administration into mammals and provides sustained and prolonged drug release till 24 hours which helps to reduce dosing frequency. The composition comprises therapeutically effective amount of active substance, release retarding polymers and other pharmaceutically acceptable excipients.
PCT/IN2010/000137 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants WO2010103544A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10740754A EP2405900A2 (en) 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
CN2010800196712A CN102438597A (en) 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
EA201171109A EA201171109A1 (en) 2009-03-09 2010-03-09 NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN522/MUM/2009 2009-03-09
IN522MU2009 2009-03-09

Publications (3)

Publication Number Publication Date
WO2010103544A2 WO2010103544A2 (en) 2010-09-16
WO2010103544A3 true WO2010103544A3 (en) 2011-04-07
WO2010103544A4 WO2010103544A4 (en) 2011-06-03

Family

ID=42728892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000137 WO2010103544A2 (en) 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants

Country Status (5)

Country Link
EP (1) EP2405900A2 (en)
CN (1) CN102438597A (en)
EA (1) EA201171109A1 (en)
GE (1) GEP20135986B (en)
WO (1) WO2010103544A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005500A2 (en) 2010-07-06 2012-01-12 주식회사 네비팜 Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
WO2012172413A1 (en) 2011-06-16 2012-12-20 Abbott Healthcare Pvt. Ltd. Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof
KR101156054B1 (en) * 2011-09-05 2012-06-20 주식회사 네비팜 A stable and control-released pharmaceutical composition comprising eperisone
KR101832842B1 (en) * 2012-01-13 2018-02-27 한미약품 주식회사 Pharmaceutical composition with an improved stability comprising eperisone or a pharmaceutically acceptable salt thereof and specific acidifying agent
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
CN102895206A (en) * 2012-10-31 2013-01-30 中国药科大学 Rhizoma bletillae polysaccharide gastric-floating tablet and preparation method and application thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
KR101497354B1 (en) * 2013-03-29 2015-03-02 초당약품공업 주식회사 Slow release pharmaceutical composition having Eperisone as active ingredient
CN103432093B (en) * 2013-08-31 2015-03-25 西南大学 Pridinol methanesulfonate matrix sustained-release tablet and preparation method thereof
PL2848261T3 (en) * 2013-09-12 2016-10-31 Pharmaceutical formulations comprising a muscle relaxant and an analgesic combination
HUE029193T2 (en) * 2013-09-12 2017-02-28 Sanovel Ilac Sanayi Ve Ticaret As Sustained release pharmaceutical formulations of Thiocolchicoside
PL2848260T3 (en) * 2013-09-12 2016-09-30 Novel formulations of thiocolchicoside
CN104688709A (en) * 2015-03-24 2015-06-10 北京世桥生物制药有限公司 Fumaric acid quetiapine composition sustained-release tablet and preparing method thereof
WO2018044020A1 (en) * 2016-08-29 2018-03-08 초당약품공업 주식회사 Method for preparing eperisone sustained release microsphere, and composite preparation of eperisone sustained release microsphere and aceclofenac
TR201720289A2 (en) * 2017-12-13 2019-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tolperizon and Selective COX-2 Inhibitor Combinations
TR201720293A2 (en) 2017-12-13 2019-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tolperisone and non-selective cox inhibitor combinations
TR201819202A2 (en) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT
TR201906487A1 (en) * 2019-04-30 2020-11-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS CONTAINING TOLPERISONE AND NIMESULIDE COMBINATIONS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295411A1 (en) * 1987-05-15 1988-12-21 Sansho Co., Ltd. Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
EP1163902A2 (en) * 2000-06-16 2001-12-19 Pacific Corporation Transdermal preparation containing hydrophilic or salt-form drug
WO2004032927A1 (en) * 2002-10-11 2004-04-22 Amorepacific Corporation Transdermal preparations comprising eperisone, tolperisone or salts thereof
US20050196451A1 (en) * 2004-03-05 2005-09-08 Angelika Bodenteich Tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration
WO2009013552A1 (en) * 2007-07-23 2009-01-29 Richter Gedeon Nyrt. Controlled release pharmaceutical composition of tolperison hydrochloride

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485915A (en) 1987-09-28 1989-03-30 Eisai Co Ltd Hypotensor
US5498422A (en) 1991-04-08 1996-03-12 Nippon Shinyaku Company Limited Sustained release capsule
AT409083B (en) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag PHARMACEUTICAL PREPARATION CONTAINING TOLPERISON FOR ORAL ADMINISTRATION
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
US20060004050A1 (en) 2004-07-02 2006-01-05 Speicher Brian T Compositions and methods for the prevention or treatment of pain and other nervous system disorders
CN101002752A (en) * 2005-09-26 2007-07-25 刘凤鸣 Slow release preparation of tropyone
WO2008004127A2 (en) 2006-04-20 2008-01-10 Sanochemia Pharmazeutika Ag Method for administering tolperisone

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295411A1 (en) * 1987-05-15 1988-12-21 Sansho Co., Ltd. Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
EP1163902A2 (en) * 2000-06-16 2001-12-19 Pacific Corporation Transdermal preparation containing hydrophilic or salt-form drug
WO2004032927A1 (en) * 2002-10-11 2004-04-22 Amorepacific Corporation Transdermal preparations comprising eperisone, tolperisone or salts thereof
US20050196451A1 (en) * 2004-03-05 2005-09-08 Angelika Bodenteich Tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration
WO2009013552A1 (en) * 2007-07-23 2009-01-29 Richter Gedeon Nyrt. Controlled release pharmaceutical composition of tolperison hydrochloride

Also Published As

Publication number Publication date
WO2010103544A2 (en) 2010-09-16
EP2405900A2 (en) 2012-01-18
CN102438597A (en) 2012-05-02
EA201171109A1 (en) 2012-03-30
GEP20135986B (en) 2013-12-10
WO2010103544A4 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
JP2009102342A5 (en)
WO2001087284A3 (en) Aldosterone antagonist composition for release during aldosterone acrophase
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
WO2004108162A3 (en) Controlled release pharmaceutical composition
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
EA200700049A1 (en) PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL
WO2012007159A3 (en) Novel gastro-retentive dosage forms
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2005515966A5 (en)
JP2013542247A5 (en)
EA200901277A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DAPAGLYFLOSINE PROPYLENE GLYCOLHYDRATE
HRP20220902T3 (en) Compositions and uses for treating multiple sclerosis
WO2007106550A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
UA116334C2 (en) SOLID FORMS OF BENDAMUSTINE DOSAGE
WO2008023016A3 (en) Galenic formulations of aliskiren
MA33463B1 (en) FIXED SOLID PHARMACEUTICAL DOSE COMPOSITIONS COMPRISING IRBESARTAN AND AMLODIPINE, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
UA89795C2 (en) Pharmaceutical composition comprising temozolomide ester
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080019671.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12011501791

Country of ref document: PH

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10740754

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12409

Country of ref document: GE

Ref document number: a201111780

Country of ref document: UA

Ref document number: 201171109

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2010740754

Country of ref document: EP